Previous 10 | Next 10 |
In the same way as Moderna and BioNTech, CureVac makes use of mRNA to develop COVID vaccines. However, in contrast to these two illustrious peers which are at commercialization stage, CureVac's first generation vaccine candidate has exhibited a much lower efficiency against infection....
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 31, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the publication of its pivotal Phase 2b/3 (HE...
Findings in preclinical mouse models provide first direct proof of efficacy of HNF4A mRNA therapeutics in the treatment of liver fibrosis and cirrhosis Further research aimed at optimizing mRNA therapeutic candidates for non-clinical and clinical development are ongoing T...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips RA Capital Management is a Bost0n-based hedge fund that invests in healthcare and life sciences companies. It is also Novavax’s (NASDAQ: NVAX ) third-largest shareholder. As of April 19, 2021, RA Capital o...
President Joe Biden said on Friday that Federal health authorities are discussing moving up the timeline for coronavirus booster shots sooner than the planned eight-month window, CNBC reports. “We’re considering the advice you’ve given that we should start earlier,”...
CureVac (NASDAQ: CVAC) recently announced that Boehringer Ingelheim terminated a partnership on a messenger RNA lung cancer vaccine program. In this Motley Fool Live video recorded on Aug. 18 , Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not t...
Pfizer (NYSE:PFE) - BioNTech's (NASDAQ:BNTX) coronavirus vaccine was linked to side effects like increased risk of myocarditis, an inflammation of the heart muscle. But, according to a study published in the New England Journal of Medicine, the risk of heart inflammation is higher in people i...
According to the latest update by the U.S. Centers for Disease Control and Prevention (CDC), some 25% of COVID-19 infections among Los Angeles County residents occurred in fully vaccinated people from May through July 25. Among fully vaccinated persons on July 25, 55.2% had received the Pfize...
Following full FDA approval of Pfizer (NYSE:PFE) - BioNTech's (NASDAQ:BNTX) COVID-19 vaccine for people of age 16 years and above, President Joe Biden has called on corporates to impose vaccine requirements for employees, Bloomberg reports. “Today I’m calling on more companies i...
Amid surge in number of new daily coronavirus cases as Delta variant spreads, Israel has approved offering a third dose of Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine to people of age above 40 and teachers - Reuters. The third dose will only be given to people who had rece...
News, Short Squeeze, Breakout and More Instantly...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent ...
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone pa...
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA tec...